Who Should Attend

A GCP audit can lead to the detection of problems with the conduct of the clinical trial.  It is important to understand the differences between lack of knowledge and poor execution vs. actual misconduct and fraud.  This two-day course will discuss some of the common issues seen in clinical trials, how to handle problem findings and how to distinguish between poor performance and misconduct.

This course will benefit those involved in the monitoring and/or QA of clinical trials.  Attendees who work for Pharmaceutical firms, Medical Device companies, Contract Research Organizations (CRO), Institutional Review Boards (IRBs) and academic institutions involved with the supervision or oversight of clinical trial practices and quality will find this course to be highly beneficial.



Learning Objectives

Upon completion, attendees will be able to:

• Identify and define the principles and requirements for GCPs
• Define the basic roles and responsibilities of the sponsor, monitor, investigators and FDA as they relate to the quality of clinical trials
• Understand the GCP audit process for sponsors
• When to conduct audits of vendors, sites, IRBs and laboratories
• Ensure that your data and supporting documentation are accurate and presentable for inspection
• Gain knowledge concerning common outcomes and findings in clinical trials
• How to respond to an audit to avoid further regulatory consequences
• Learn how to detect and prevent fraud and misconduct in clinical trials
• Understand telltale signs which may indicate fraud and/or misconduct
• Through the use of examples, fully understand the consequences which result when proper procedures are not followed 

Case study analysis, exercises and videos will be used throughout the course to provide insight and promote discussion.

Course Description

This course provides a solid understanding of GCP requirements and clinical quality assurance in detecting fraud and misconduct in clinical trials.  Attendees will gain experience in detecting, correcting and preventing clinical study misconduct and fraud at domestic and international clinical sites.

Additionally, attendees with learn how to ensure that their study conduct and supporting documentation is accurate and factual.  The course will also address how to uncover misconduct, as well as, dealing with its consequences while identifying proactive solutions to prevent further problems.  Included in the course work are practical examples and a roadmap for evaluating study conduct, source documents, case report forms and other study documentation through presentation and interactive case studies.

Additionally, the course will cover methods to detect misconduct and deal with fraud in clinical trials by:

• Defining the basic requirements of Good Clinical Practices
• Determining the appropriate duties and oversight required of the sponsor, monitor and investigators to ensure a high level of quality in a clinical trial
• Understanding how GCPs can impact clinical research programs
• Ensuring that quality practices are designed and implemented to guarantee complaint clinical trials
• Learning how to effectively manage a Sponsor, as well as, an FDA GCP inspection
• Developing mechanisms to uncover and preclude fraud and misconduct in clinical trials
• Building trial guidelines/structure which will easily identify any misconduct and which is capable of quickly addressing any issues that arise in order to avoid regulatory consequences